论文部分内容阅读
目的探究他汀类与心血管药物配伍的安全性。方法 98例慢性心力衰竭患者,根据单双号方法分为观察组及对照组,各49例。对照组给予常规治疗,观察组则在此基础上增加他汀类药物治疗,对比两组患者治疗疗效。结果治疗后,观察组总有效率(89.80%)明显高于对照组(75.51%)(P<0.05);同时对比其血药浓度-时间曲线下面积(AUC)以及药峰浓度(Cmax),差异具有统计学意义(P<0.05);两组患者的血药浓度以及半衰期比较,差异无统计学意义(P>0.05)。结论采用他汀类与心血管药物配伍治疗时应对患者的药代动力学进行观察,从而采用针对性药物予以治疗,以此来减少不良反应现象的发生。
Objective To investigate the safety of compatibility of statins and cardiovascular drugs. Methods A total of 98 patients with chronic heart failure were divided into observation group and control group according to single and double number method, 49 cases in each group. The control group was given routine treatment, while the observation group was given statin therapy on the basis of this comparison, and the curative effect was compared between the two groups. Results After treatment, the total effective rate (89.80%) in the observation group was significantly higher than that in the control group (75.51%) (P <0.05). The AUC and Cmax of the observation group were also compared. The difference was statistically significant (P <0.05). There was no significant difference in plasma concentration and half-life between the two groups (P> 0.05). Conclusions The pharmacokinetics of patients should be observed when statins and cardiovascular drugs are used in combination, so as to reduce the incidence of adverse reactions by using targeted drugs.